APA (7th ed.) Citation

Song, Z., Park, J., Zhang, Y., Coward, J., Voskoboynik, M., Kichenadasse, G., . . . Liu, S. (2025). 922MO Updated ongoing phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors. Annals of Oncology, 36, S603. https://doi.org/10.1016/j.annonc.2025.08.1491

Chicago Style (17th ed.) Citation

Song, Z., et al. "922MO Updated Ongoing Phase I/II Clinical Trial Results of AMT-116, a First-in-class Anti-CD44v9 Antibody-drug Conjugate (ADC), in Patients with Advanced Solid Tumors." Annals of Oncology 36 (2025): S603. https://doi.org/10.1016/j.annonc.2025.08.1491.

MLA (9th ed.) Citation

Song, Z., et al. "922MO Updated Ongoing Phase I/II Clinical Trial Results of AMT-116, a First-in-class Anti-CD44v9 Antibody-drug Conjugate (ADC), in Patients with Advanced Solid Tumors." Annals of Oncology, vol. 36, 2025, p. S603, https://doi.org/10.1016/j.annonc.2025.08.1491.